{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:18:07Z","timestamp":1792289887191,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,8,24]],"date-time":"2012-08-24T00:00:00Z","timestamp":1345766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12325-012-0045-5","type":"journal-article","created":{"date-parts":[[2012,8,25]],"date-time":"2012-08-25T06:47:52Z","timestamp":1345877272000},"page":"736-746","source":"Crossref","is-referenced-by-count":81,"title":["Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials"],"prefix":"10.1007","volume":"29","author":[{"given":"Matteo","family":"Monami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Toffanello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Ragghianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Monami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,24]]},"reference":[{"key":"45_CR1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2337\/dc06-2558","volume":"30","author":"A. Avogaro","year":"2007","unstructured":"Avogaro A, Giorda C, Maggini M, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30:1241\u20131247.","journal-title":"Diabetes Care"},{"key":"45_CR2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P. Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580\u2013591.","journal-title":"N Engl J Med"},{"key":"45_CR3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of Medical Care in Diabetes 2012. Available at: care.diabetesjournals.org\/content\/35\/Supplement_1\/S11.full.pdf+html . Accessed Jan 1 2012.","DOI":"10.2337\/dc13-S011"},{"key":"45_CR4","unstructured":"International Diabetes Federation. Guide for Guidelines. Available at: www.idf.org\/webdata\/docs\/Guide-for-Guidelines.pdf . Accessed Jan 1 2012."},{"key":"45_CR5","unstructured":"Societa Italiana de Diabetologia. Guidelines [in Italian]. Available at: www.siditalia.it\/pubblicazioni\/linee-guida.html . Accessed Jan 1 2012."},{"key":"45_CR6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8227(00)00211-4","volume":"51","author":"C.E. Tan","year":"2001","unstructured":"Tan CE, Chew LS, Chio LF et al. Cardiovascular risk factors and LDL subfraction profile in type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract. 2001;51:107\u2013114.","journal-title":"Diabetes Res Clin Pract"},{"key":"45_CR7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1365-2362.2000.00702.x","volume":"30","author":"L. Duvillard","year":"2000","unstructured":"Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in noninsulin- dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest. 2000;30:685\u2013694.","journal-title":"Eur J Clin Invest"},{"key":"45_CR8","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1001\/jama.1990.03440210043030","volume":"263","author":"S.M. Haffner","year":"1990","unstructured":"Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893\u20132898.","journal-title":"JAMA"},{"issue":"Suppl.3","key":"45_CR9","first-page":"32","volume":"25","author":"B.L. Verges","year":"1999","unstructured":"Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab. 1999;25(Suppl. 3):32\u201340.","journal-title":"Diabetes Metab"},{"key":"45_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157488408784293688","volume":"3","author":"G. Derosa","year":"2008","unstructured":"Derosa G, Salvadeo SA. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Clin Pharmacol. 2008;3:77\u201384.","journal-title":"Curr Clin Pharmacol"},{"key":"45_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2796.2004.01328.x","volume":"256","author":"M.G. Wulffel\u00e9","year":"2004","unstructured":"Wulffel\u00e9 MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1\u201314.","journal-title":"J Intern Med"},{"key":"45_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1463-1326.2006.00698.x","volume":"9","author":"J. Rosenstock","year":"2007","unstructured":"Rosenstock J, Kim SW, Baron MA et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175\u2013185.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1463-1326.2007.00839.x","volume":"10","author":"R. Scott","year":"2008","unstructured":"Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959\u2013969.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12325-011-0088-z","volume":"29","author":"M. Monami","year":"2012","unstructured":"Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29:14\u201325.","journal-title":"Adv Ther"},{"key":"45_CR15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1463-1326.2009.01187.x","volume":"12","author":"P. Aschner","year":"2010","unstructured":"Aschner P, Katzeff HL, Guo H, Sunga S, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:252\u2013261.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1462-8902.2004.00325.x","volume":"6","author":"J.B. Buse","year":"2004","unstructured":"Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6:133\u2013156.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","volume":"290","author":"J.L. Chiasson","year":"2003","unstructured":"Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486\u2013494.","journal-title":"JAMA"},{"key":"45_CR18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2174\/157339908786241133","volume":"4","author":"I. Eleftheriadou","year":"2008","unstructured":"Eleftheriadou I, Grigoropoulou P, Katsilambros N, Tentolouris N. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev. 2008;4:340\u2013356.","journal-title":"Curr Diabetes Rev"},{"key":"45_CR19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/ENDO:29:1:143","volume":"29","author":"Y. Mori","year":"2006","unstructured":"Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine. 2006;29:143\u2013148.","journal-title":"Endocrine"},{"key":"45_CR20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.metabol.2008.09.006","volume":"58","author":"T. Araki","year":"2009","unstructured":"Araki T, Emoto M, Konishi T et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism. 2009;58:143\u2013148.","journal-title":"Metabolism"},{"key":"45_CR21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.diabres.2007.08.024","volume":"79","author":"M. Monami","year":"2008","unstructured":"Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a metaanalysis. Diabetes Res Clin Pract. 2008;79:196\u2013203.","journal-title":"Diabetes Res Clin Pract"},{"key":"45_CR22","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","volume":"303","author":"O.J. Phung","year":"2010","unstructured":"Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410\u20131418.","journal-title":"JAMA"},{"key":"45_CR23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D. Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u2013269.","journal-title":"Ann Intern Med"},{"key":"45_CR24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"C.B. Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u20131101.","journal-title":"Biometrics"},{"key":"45_CR25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M. Egger","year":"1997","unstructured":"Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u2013634.","journal-title":"BMJ"},{"key":"45_CR26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0002-9343(99)80343-X","volume":"98","author":"R.F. Coniff","year":"1995","unstructured":"Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulindependent diabetes mellitus. Am J Med. 1995;98:443\u2013451.","journal-title":"Am J Med"},{"key":"45_CR27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","volume":"333","author":"R.A. DeFronzo","year":"1995","unstructured":"DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541\u2013549.","journal-title":"N Engl J Med"},{"key":"45_CR28","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.21.9.1462","volume":"21","author":"E.S. Horton","year":"1998","unstructured":"Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care. 1998;21:1462\u20131469.","journal-title":"Diabetes Care"},{"key":"45_CR29","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"J.A. Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u20131289.","journal-title":"Lancet"},{"key":"45_CR30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","volume":"23","author":"S. Aronoff","year":"2000","unstructured":"Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebocontrolled dose-response study. Diabetes Care. 2000;23:1605\u20131611.","journal-title":"Diabetes Care"},{"key":"45_CR31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.clinthera.2005.05.005","volume":"27","author":"V. Mattoo","year":"2005","unstructured":"Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallelgroup study. Clin Ther. 2005;27:554\u2013567.","journal-title":"Clin Ther"},{"key":"45_CR32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1463-1326.2010.01204.x","volume":"12","author":"D. Williams-Herman","year":"2010","unstructured":"Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:442\u2013451.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1463-1326.2006.00698.x","volume":"9","author":"J. Rosenstock","year":"2007","unstructured":"Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175\u2013185.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-2007-970422","volume":"39","author":"S. Dejager","year":"2007","unstructured":"Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39:218\u2013223.","journal-title":"Horm Metab Res"},{"key":"45_CR35","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/dc08-1035","volume":"31","author":"R.A. DeFronzo","year":"2008","unstructured":"DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315\u20132317.","journal-title":"Diabetes Care"},{"key":"45_CR36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2008.01016.x","volume":"11","author":"R.E. Pratley","year":"2009","unstructured":"Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11:167\u2013176.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","volume":"13","author":"M.R. Taskinen","year":"2011","unstructured":"Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR38","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2009-0550","volume":"94","author":"P. Hollander","year":"2010","unstructured":"Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2010;94:4810\u20134819.","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR39","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","volume":"28","author":"J. Rosenstock","year":"2006","unstructured":"Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24- week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556\u20131568.","journal-title":"Clin Ther"},{"key":"45_CR40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1742-1241.2010.02589.x","volume":"65","author":"K.H. Yoon","year":"2011","unstructured":"Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of \u03b2-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65:154\u2013164.","journal-title":"Int J Clin Pract"},{"key":"45_CR41","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","volume":"29","author":"B. Charbonnel","year":"2006","unstructured":"Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638\u20132643.","journal-title":"Diabetes Care"},{"key":"45_CR42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1463-1326.2009.01056.x","volume":"11","author":"M. Jadzinsky","year":"2009","unstructured":"Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611\u2013622.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1185\/030079907X178766","volume":"23","author":"C. Levetan","year":"2007","unstructured":"Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin. 2007;23:945\u2013952.","journal-title":"Curr Med Res Opin"},{"key":"45_CR44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1620\/tjem.223.133","volume":"223","author":"S. Ogawa","year":"2011","unstructured":"Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223:133\u2013135.","journal-title":"Tohoku J Exp Med"},{"key":"45_CR45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5414\/CPP41421","volume":"41","author":"H.W. Breuer","year":"2003","unstructured":"Breuer HW. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther. 2003;41:421\u2013440.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"45_CR46","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.2174\/138161209789057995","volume":"15","author":"N. Papanas","year":"2009","unstructured":"Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des. 2009;15:3179\u20133192.","journal-title":"Curr Pharm Des"},{"key":"45_CR47","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1055\/s-0031-1275704","volume":"43","author":"G. Derosa","year":"2011","unstructured":"Derosa G, Cicero AF, Fogari E, D\u2019Angelo A, Bianchi L, Maffioli P. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm Metab Res. 2011;43:505\u2013512.","journal-title":"Horm Metab Res"},{"key":"45_CR48","doi-asserted-by":"crossref","first-page":"1 221","DOI":"10.1111\/j.1463-1326.2007.00724.x","volume":"10","author":"E. Mannucci","year":"2008","unstructured":"Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10:1 221\u20131 238.","journal-title":"Diabetes Obes Metab"},{"key":"45_CR49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatmentrisk of complications in patients with type 2 diabetes","year":"1998","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837\u2013853.","journal-title":"Lancet"},{"key":"45_CR50","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes","year":"1998","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854\u2013865.","journal-title":"Lancet"},{"issue":"Suppl.3","key":"45_CR51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1185\/03007995.2011.602964","volume":"27","author":"M. Monami","year":"2011","unstructured":"Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors. A metaanalysis of randomized clinical trials. Curr Med Res Opin. 2011;27(Suppl. 3):57\u201364.","journal-title":"Curr Med Res Opin"},{"key":"45_CR52","unstructured":"AstraZeneca. SAVOR-TIMI 53 (Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications). Identifier: NCT01107886. Available at: clinicaltrials.gov\/ct2\/show\/NCT01107886?term =type+2+diabetes+mellitus+and+cardiovascular+di sease&rank=37. Accessed Dec 27 2011."},{"key":"45_CR53","unstructured":"Merck. TECOS (Sitagliptin Cardiovascular Outcome Study). Identifier: NCT 00790205. Available at: clinicaltrials.gov\/ct2\/show\/NCT00790205. Accessed Dec 27 2011."},{"key":"45_CR54","unstructured":"Takeda Global Research & Development Center, Inc. Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE). Identifier: NCT00968708. Available at: clinicaltrials.gov\/ct2\/show\/NCT00968708. Accessed Dec 27 2011."},{"key":"45_CR55","unstructured":"Boehringer Ingelheim Pharmaceuticals. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes. Identifier: NCT01243424. Available at: clinicaltrials.gov\/ct2\/show\/ NCT01243424. Accessed Dec 27 2011."},{"key":"45_CR56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jacc.2010.06.055","volume":"57","author":"S.J. Nicholls","year":"2011","unstructured":"Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride\/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol. 2011;57:153\u2013159.","journal-title":"J Am Coll Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0045-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-012-0045-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0045-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:13:23Z","timestamp":1562112803000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-012-0045-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,24]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s12325-012-0045-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,24]]}}}